申请人:GLAXO GROUP LIMITED
公开号:EP0291172A1
公开(公告)日:1988-11-17
The present invention provides ketones of the general formula (I):
and physiologically acceptable salts and solvates thereof, wherein R¹ and R², which may be the same or different, each represents a hydrogen atom or a C₁₋₆alkyl group;
Im represents an imidazolyl group of formula:
wherein one of the groups represented by R³, R⁴ and R⁵ is a hydrogen atom or a C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₆alkenyl, phenyl or phenylC₁₋₃alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C₁₋₆alkyl group; and
A is a group of the formula (a), (b), (c), (d), (e), (f) or (g):
and when A is the group (g), the group -COCR¹R²CH₂Im is attached at the 2- or 4- position of the indole moiety.
The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT₃ receptors and are useful, for example, in the treatment of psychotic disorders, anxiety and nausea and vomiting.
本发明提供通式(I)的酮类化合物:
及其生理学上可接受的盐和溶剂,其中 R¹ 和 R² 可以相同或不同,各自代表氢原子或 C₁₋₆ 烷基;
Im 代表式中的咪唑基团:
其中 R³、R⁴ 和 R⁵ 所代表的基团之一是氢原子或 C₁₋₆ 烷基、C₃₋₇ 环烷基、C₃₋₆、苯基或苯基 C₁₋₃烷基,而另外两个基团(可以相同或不同)分别代表氢原子或 C₁₋₆烷基;且
A 是式 (a)、(b)、(c)、(d)、(e)、(f) 或 (g) 的基团:
当 A 为(g)基团时,在吲哚分子的 2-或 4-位连接基团-COCR¹R²CH₂Im。
这些化合物是 5-HT 在 5-HT₃ 受体上的强效选择性拮抗剂,可用于治疗精神障碍、焦虑、恶心和呕吐等疾病。